NewAmsterdam's pooled Phase 3 data; C4 seeks partners for solid tumor degrader

Plus, news about Vivo Capital, Arcus Biosciences, Rigel and Voyager Therapeutics: NewAmsterdam shares pooled Phase 3 data: The company’s experimental CETP inhibitor obicetrapib reduced lipoprotein(a) levels by a median of 45 ...